limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 25, 2002.

Time: 2:30 PM to 5:00 PM.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Everett E. Sinnett, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2178, MSC 7818, Bethesda, MD 20892. (301) 435–1016. *sinnett@nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 25, 2002.

Time: 12:45 PM to 1:30 PM.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Cheri Wiggs, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3180, MSC 7848, Bethesda, MD 20892. (301) 435–1261.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 26, 2002.

Time: 1:00 PM to 2:00 PM.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: David L. Simpson, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5192, MSC 7846, Bethesda, MD 20892. (301) 435–1278. *simpsod@mail.nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 26, 2002.

Time: 1:00 PM to 2:00 PM.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Jim Bishop, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5180, MSC 7844, Bethesda, MD 20892. (301) 435–1250.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 26, 2002.

Time: 1:00 PM to 2:30 PM.

Agenda: To review and evaluate grant applications.

Place: NIH Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Michael A. Oxman, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4112, MSC 7848, Bethesda, MD 20892. 301–435–3565. *oxmanm@csr.nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 27, 2002.

Time: 2:00 PM to 3:00 PM.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person Lee Rosen, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5116, MSC 7854, Bethesda, MD 20892. (301) 435–1171.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 26, 2002.

Time: 3:00 PM to 5:00 PM.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Philip Perkins, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7804, Bethesda, MD 20892. (301) 435–1718.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 26, 2002.

Time: 3:15 PM to 5:45 PM.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Everett E. Sinnett, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2178, MSC 7818, Bethesda, MD 20892. (301) 435–1016. *sinnett@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 26, 2002.

Time: 12 PM to 1:30 PM.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Elaine Sierra-Rivera, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4136, MSC 7804, Bethesda, MD 20892. (301) 435–1779. *riverse@csr.nih.gov.*

(Catalog of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393–93,396, 93.837–93,844, 93.846–93.878, 93.892, 93.893, National Institute of Health, HHS)

Dated: March 7, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02–6054 Filed 3–12–02; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Co-Exclusive License: Human Derived Monocyte Attracting Purified Peptide Products for Treating Human Infections and Neoplasms in a Human Body

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a co-exclusive license to practice the inventions embodied in the U.S. Patent Applications and issued Patents listed below to Centocor Corporation, having a place of business in Malvern, Pennsylvania. The patent rights of these inventions have been assigned to the United States of America.

- USPA 07/330,446 filed March 30, 1989 and entitled ''Human Derived Monocyte Attracting Purified Peptide Products Useful in a Method of Treating Infections and Neoplasms in a Human Body and the Cloning of Full Length cDNA Thereof''
- USPA 07/686,264 filed April 15, 1991 now USPN 6,090,795 issued July 18, 2000
- USPA 08/449,552 filed May 24, 1995 now USPN 5,532,144 issued July 2, 1996
- USPA 08/466,288 filed June 6, 1995 now USPN 5,714,578 issued February 3, 1998
- PCT/US90/00040 filed January 2, 1990

The prospective co-exclusive license territory will be worldwide and the field of use may be limited to the treatment of asthma, restenosis, hepatitis B and cancer. This announcement serves as a modification of a notice previously published in the **Federal Register**, 66 FR 59450–59451, Nov. 28, 2001.

DATES: Only written comments and/or license applications which are received by the National Institutes of Health on or before May 13, 2002, will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comment and other materials relating to the contemplated co-exclusive license should be directed to: Percy S. Pan, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone

301–496–7736 x256; Facsimile 301–402–0220; e-mail *panp@od.nih.gov.*

SUPPLEMENTARY INFORMATION: The invention relates to a human derived purified peptide product that exhibits monocytic chemotactic activity (MCA). A method of preparing the peptide is disclosed as well as a method of treating neoplasms and infections by administering the peptides. A pharmaceutical composition of the peptide is also claimed. The peptide may be useful in the treatment of various disorders including autoimmune disease, chronic inflammatory diseases, and cancer. This peptide, also known as MCP–1, is a b chemokine. Chemokines are multipotent cytokines that localize and enhance inflammation by inducting chemotaxis and activation of different types of inflammatory cells. This peptide is a chemotactic factor for monocytes. It stimulates histamine release and regulates cytokine production in monocytes.

The prospective co-exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective co-exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated co-exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 7, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–6061 Filed 3–12–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Uses of Cyanovirin-N for HIV Vaccines

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive worldwide license to practice the inventions embodied in patents under ''Supplementary Information'' to OmniViral Therapeutics LLC, having a place of business in Gaithersburg, Maryland. The patent rights in these inventions have been assigned to the Government of the United States of America.

The field of use may be limited to four vaccine strategies based on:

1. Conjugate consisting of HIV virions inactivated with Cyanovirin–N or homolog thereof

2. Conjugate consisting of gp120, an HIV envelope protein, and Cyanovirin–N or homolog thereof

3. Native Cyanovirin–N or homolog thereof to stimulate a virus neutralizing response via endogenous anti-idiotypic antibodies

4. Identification of Cyanovirin-N-binding-site anti-idiotypic monoclonal antibodies, and use thereof as a primary antigen

DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 13, 2002, will be considered.

ADDRESSES: Requests for a copy of this patent application, inquiries, comments and other materials relating to the contemplated license should be directed to Cristina Thalhammer-Reyero, Ph.D., M.B.A., Technology Transfer Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852; Telephone: (301) 496–7056 extension 263; Facsimile: (301) 402–0220; E-mail: thalhamc@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The patents and patent applications to be licensed are:

Patent No 6,245,737, issued 06/12/2001, entitled ''Conjugates of Antiviral Proteins or Peptides and Virus or Viral Envelope Glycoproteins'', (E–117–95/7);

PCT/US99/18975 (WO00/11036), filed Aug. 19, 1998, allowed, entitled ''An Anti-Cyanovirin Antibody with an Internal Image of gp120, a Method of Use Thereof, and a Method of Using a Cyanovirin to Induce an Immune Response to gp120'' (E–117–95/8);

PCT/US00/06247 (WO00/53213) filed March 10 2000, pending, entitled ''Cyanovirin Conjugates, Matrix-Anchored Cyanovirin And Anti-Cyanovirin Antibody, And Related Compositions And Methods of Use'' (E–074–99/2);

US Patent No. 6,015,876, issued 01/18/2000, entitled ''Methods Of Using Cyanovirins'' (E–074–99/3);

USSN 09/428,275 filed 10/27/1999, pending, entitled ''Methods of Using Cyanovirins to Inhibit Viral Infection'' (E–074–99/5);

USSN 09/714,884 filed 03/22/2001, pending, entitled ''Conjugates of Antiviral Proteins or Peptides and Virus or Viral Envelope Glycoproteins'' (E–074–99/8);

US Patent No. 5,843,882, issued Dec. 01, 1998, entitled ''Antiviral Proteins and Peptides'' (E–117–95/0);

US Patent No. 5,821,081, issued Oct. 13, 1998, entitled ''Nucleic Acids Encoding Antiviral Proteins and Peptides, Vectors and Host Cells Comprising Same, and Methods of Producing the Antiviral Proteins and Peptides'' (E–117–95/1);

US Patent No. 6,015,876, issued Jan. 18, 2000, entitled ''Method of Using Cyanovirins (E–117–95/3);

US Patent No. 5,998,587, issued Dec. 7, 1999, entitled ''Anti-Cyanovirin Antibody'' (E–117–95/6);

And related U.S. and foreign cognates of the PCT patent applications.

The inventors have found that Cyanovirin-N, a naturally occurring anti-HIV protein originally isolated from *Nostoc ellipipsosporum*, a blue-green algae, has potent neutralizing activity against HIV 1 and 2 by blocking the fusion reaction between HIV and CD4 cells. Cyanovirin-N is now expressed in a DNA coding sequence in *E. coli.* New information on the nature of the interaction of the HIV envelope with the cell surface during the binding, entry and fusion process has led to new ideas about how to improve envelope immunogenicity. Among these ideas are the various ways of using Cyanovirin-N in preparing reagents for use in a potential HIV vaccine.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Comments and objections submitted in response to this notice will not be made available for